Compare RVMD & AXON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVMD | AXON |
|---|---|---|
| Founded | 2014 | 1993 |
| Country | United States | United States |
| Employees | 883 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Ordnance And Accessories |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1B | 33.2B |
| IPO Year | N/A | 2001 |
| Metric | RVMD | AXON |
|---|---|---|
| Price | $161.65 | $418.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 19 | 16 |
| Target Price | $140.84 | ★ $758.80 |
| AVG Volume (30 Days) | ★ 2.5M | 1.1M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.05 |
| Revenue | N/A | ★ $2,779,536,000.00 |
| Revenue This Year | N/A | $31.50 |
| Revenue Next Year | $533.02 | $28.95 |
| P/E Ratio | ★ N/A | $204.61 |
| Revenue Growth | N/A | ★ 33.47 |
| 52 Week Low | $34.00 | $339.01 |
| 52 Week High | $166.50 | $885.92 |
| Indicator | RVMD | AXON |
|---|---|---|
| Relative Strength Index (RSI) | 61.78 | 45.75 |
| Support Level | $141.22 | $403.48 |
| Resistance Level | $166.50 | $587.37 |
| Average True Range (ATR) | 6.70 | 28.33 |
| MACD | 0.20 | -5.72 |
| Stochastic Oscillator | 85.99 | 18.80 |
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Axon Enterprise Inc is building a public safety operating system by integrating a suite of hardware devices and cloud software solutions. The company's suite includes cloud-hosted digital evidence management solutions, TASER energy devices, drones and robotic security, and training solutions. Its operation comprises of two operating segments, Software and Services, and Connected Devices. The company generates the majority of its revenue from the Connected Devices segment, which is engaged in developing, manufacturing, and selling fully integrated hardware solutions such as conducted energy devices sold under the TASER brand, body cameras, fixed and in-car cameras, drone and counter-drone technologies, and a broad ecosystem of accessories, extended warranties and related hardware products.